CareDx first sued Natera in April 2019, accusing the company of trying to mislead patients and clinicians about the superiority of its Prospera transplant test.
The Milwaukee, Wisconsin-based firm is part of a growing biotech ecosystem in the region, which has particular expertise in transplant medicine.
The test adds to a menu of transplant monitoring assays that includes cytomegalovirus, Epstein-Barr virus, and BK virus.
The patent, which was awarded Jan. 7, covers cell-free DNA-based diagnostic methods, including those used in transplant medicine.
The company said preliminary revenues for full-year 2019 are expected to increase 66 percent year over year.
The AlloSeq cfDNA kit is used to quantify the level of donor-derived cell-free DNA in transplant recipients in order to measure graft health.
The magistrate did recommend that the court dismiss two counts made against Natera with respect to trademark disparagement and unfair trade practices.
Effective Feb. 3, 2020, the donor-derived cell-free DNA test will be covered for all kidney transplant recipients, including those with multiple kidney transplants.
AlloSure 3.0 can diagnose the very early stages of T-cell mediated rejection, allowing clinicians to begin anti-rejection therapies and monitor treatment.
The company expects to launch Signatera for clinical use in colorectal cancer next year and has started to recruit a sales team for the assay.